Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why

Key Takeaways AGIO shares dropped after mixed phase III RISE UP data for Pyrukynd in SCD weakened investor confidence. AGIO said the study improved hemoglobin levels but failed to cut the annualized sickle cell pain crisis rates.Agios faced a three-month FDA review extension for mitapivat in thalassemia before the U.S. approval. Shares of Agios Pharmaceuticals (AGIO) have plunged 23% over the past six months, primarily due to pipeline and regulatory setbacks, which have dampened investor confidence in the c ...